NASDAQ:VERA Vera Therapeutics Q1 2026 Earnings Report $34.62 -0.90 (-2.52%) As of 12:48 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Vera Therapeutics EPS ResultsActual EPS-$1.69Consensus EPS -$1.33Beat/MissMissed by -$0.36One Year Ago EPS-$0.81Vera Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$0.43 millionBeat/MissN/AYoY Revenue GrowthN/AVera Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeBefore Market OpensConference Call DateThursday, May 7, 2026Conference Call Time7:30AM ETUpcoming EarningsVera Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, August 6, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Vera Therapeutics Earnings HeadlinesVera Therapeutics: Strong IgAN Data, But Differentiation Is Still PendingMay 27, 2026 | seekingalpha.comInvestment Firm Closes Out Entire $18.1 Million Position in Biotech Stock, According to Latest SEC FilingMay 26, 2026 | fool.comGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - not chips, not funding, but power. Demand is growing 15% per year and the grid can't keep up. One small company makes the exact equipment these data centers need. They're sitting on $1.5 billion in orders, their hardware is already inside Musk's Colossus, and the stock still trades like a name nobody's heard of. Analyst Dylan Jovine is releasing the ticker for free.June 1 at 1:00 AM | Behind the Markets (Ad)Vera Therapeutics Stockholders Back Board, Governance ProposalsMay 26, 2026 | tipranks.comThe Bull Case For Vera Therapeutics (VERA) Could Change Following Atacicept’s FDA Priority Review And Ramp-UpMay 11, 2026 | finance.yahoo.comVera Therapeutics (VERA) Gets a Buy from LifeSci CapitalMay 8, 2026 | theglobeandmail.comSee More Vera Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email. Email Address About Vera TherapeuticsVera Therapeutics (NASDAQ:VERA) is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity. Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs. The company concentrates on high-unmet-need autoimmune disorders, pursuing therapies that can broadly benefit patient populations worldwide. Through strategic partnerships and disciplined clinical execution, Vera Therapeutics seeks to accelerate the translation of its immunomodulatory candidates. The leadership team at Vera Therapeutics brings extensive experience in biologics development, translational research and regulatory affairs, supported by an accomplished scientific advisory board. As a NASDAQ‐listed company trading under the ticker VERA, it is well positioned to drive its innovative platform toward key clinical milestones and deliver new treatment options for immune-mediated diseases.View Vera Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 05/25 - 05/29Gap Inc. Cuts Sales Outlook After Q1 Miss, Shares Drop 17%Costco’s Strong Quarter Still Leaves Investors With a Valuation ProblemMongoDB's AI Advantage Is Starting to Show Up in ResultsShares Fall, Targets Rise—Markets and Analysts Diverge on SynopsysBest Buy’s AI Laptop Boost Sparks Hope for a BBY TurnaroundWas Hormel’s Q2 Earnings Report the Turnaround Investors Needed? Upcoming Earnings Palo Alto Networks (6/2/2026)Broadcom (6/3/2026)CrowdStrike (6/3/2026)Medtronic (6/3/2026)Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
